Zacks Investment ResearchT3·26d ago
JANX Janux Therapeutics, Inc. Common Stock
XNAS
16.69
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
JANX
$16.69
—
Key stats
$16.69
Pre-market
$16.90
+1.26%
- 52-Week Range
- $12.12 – $35.34
- YTD
- +22.27%
- IV Rank (30D)
- 100.0
- Straddle Price
- $3.55
- P/C Vol Ratio
- 2.76
- Market Cap
- $1.0B
- Open
- $16.80
- Day Range
- $16.51 – $17.18
- Volume
- 379,225
- Prev Close
- $16.66
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.46 |
| Cost of Equity (CAPM) | 13.00% (VRP-adj) |
| WACC | 13.19% |
| Volatility Risk Premium | +104.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +2.7% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -11.1% |
| Book / Price | 89.1% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -174.7% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $17.54 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $17.19 |
| Bollinger Width / SMA20 | 78.2% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $1B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
94%
20-Day Fair Value
≈ by Nov 25, 2026
$17.02
α +2.0%
rank 86%
conviction
89%
40-Day Fair Value
≈ by Dec 24, 2026
$17.27
α +3.5%
rank 87%
conviction
92%
60-Day Fair Value
≈ by Jan 22, 2027
$17.50
α +4.8%
rank 81%
conviction
94%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.2× · 3 peers |
| Peer P/B | $52.20 | 30% | median 3.5× · 3 peers |
| Peer P/S | $1.52 | 30% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $17.54 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $15.80 | 39% | 10 strikes · skew +0.35 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.0B
- Employees
- 113
- List Date
- 2021-06-11
- CIK
- 0001817713
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- ($0.45) (7 est.)
- Headquarters
- San Diego, CA
- Homepage
- https://www.januxrx.com
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 bi…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -24.75% | 58.42% | -22.32% | -18.33% | 0.44% | -1.31% |
| Feb | -- | 9.78% | -17.71% | 469.85% | -21.82% | -2.72% | 87.48% |
| Mar | -- | -14.69% | -27.06% | -21.02% | -15.17% | 3.58% | -14.87% |
| Apr | -- | -35.09% | 23.95% | 51.23% | 23.83% | -0.96% | 12.59% |
| May | -- | 7.64% | -24.30% | -8.06% | -25.74% | 1.74% | -9.74% |
| Jun | -0.80% | 28.26% | -1.90% | -23.81% | -7.64% | 6.59% | 0.12% |
| Jul | 27.98% | 5.25% | 14.01% | -2.68% | 3.42% | 2.85% | 8.47% |
| Aug | 0.24% | -6.32% | -16.92% | 13.31% | -3.57% | 18.93% | 0.94% |
| Sep | -32.30% | 21.87% | -8.45% | 0.93% | 6.91% | -8.52% | -3.26% |
| Oct | 8.90% | 40.05% | -32.42% | 21.33% | 21.14% | -1.59%* | 9.57% |
| Nov | -27.75% | -25.26% | 35.98% | -16.88% | 24.55% | -- | -1.87% |
| Dec | 27.78% | -3.23% | 18.69% | 33.25% | -59.40% | -- | 3.42% |
| Total | -13.38% | -23.13% | -17.22% | 453.94% | -69.96% | 19.70% | 58.32% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $17.19
SMA 50: $17.54
SMA 200: $15.25
Current: $16.69
EMA 12: $17.01
EMA 26: $17.14
MACD: -0.1326 | Signal: -0.0655
BEARISH
ADX (14): 10.87
RANGE
+DI: 21.90
−DI: 22.84
Momentum Oscillators
RSI (14): 45.24
NEUTRAL
Stoch %K: 19.44
Stoch %D: 24.47
Williams %R: -85.57
Volume & Volatility
BB Upper: $18.35
BB Lower: $16.04
NEUTRAL
OBV: -48,934,606
Vol SMA 20: 766,263
Vol ROC: -52.77%
ATR: $0.80
True Range: $0.67
HV 20: 44.1%
HV 30: 46.1%
HV 60: 47.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report - JANX
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers: Strong technical momentum, positive news sentiment, and moderate volatility.
Primary Risks: Overbought conditions, potential for profit taking, and market-wide downturns.
Investment Thesis: JANX is a mid-cap biotech stock with strong technical momentum, driven by positive news sentiment and moderate volatility. While the stock has reached overbought levels, it remains in an uptrend and may continue to move higher, supported by its recent partnerships and clinical trial advancements.
Recent News Sentiment Impact: The stock's price reacted positively to the recent news headlines, especially the Bristol Myers biotech deal worth $800 million, which highlights the company's growth potential and strengthens its market position.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Bullish
- Long-term (3-12 months): Neutral
Support/Resistance Levels: The stock is trading above the SMA 200 and EMA 12, indicating strong support. Resistance lies around $16.79, which is the upper Bollinger Band.
Momentum Signals:
- RSI interpretation: Overbought (>70), potential sell signal
- MACD signal: Bullish (signal line crossover)
- Bollinger Bands position: Squeeze, breakout potential
Volume Analysis: Volume has been trending higher with the stock's price, indicating institutional interest and a strong uptrend.
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been overwhelmingly positive, highlighting the company's growth potential and partnerships.
Sentiment Assessment: Positive sentiment dominates, with 4 out of 5 headlines having a positive or neutral tone.
Catalyst Identification: Upcoming events, such as earnings announcements and product launches, could continue to drive the stock's price higher.
Market Narrative: The market narrative is focused on the company's growth potential, partnerships, and clinical trial advancements, which aligns with the technical signals indicating an uptrend.
Risk & Volatility Assessment
Beta Interpretation: JANX has a beta of 1.15, indicating above-average risk relative to the SPY.
Volatility Regime: Current volatility is moderate, which may continue to support the stock's price movements.
Options Market Signals: The options market is pricing in a $2.70 move by expiration, with a relatively low IV rank and a put/call volume ratio indicating bullish sentiment.
Downside Protection: Support lies around $14.85, which is the lower Bollinger Band, but the stock's price has shown resilience in this area before.
Market Context & Positioning
Sector Performance: JANX is outperforming its sector peers, with a relative strength index (RSI) of 0.83.
Institutional Activity: Institutional interest is moderate, with a volume rate of change of -3.25%.
Correlation Analysis: The stock has a low correlation coefficient with the market, indicating it may not be heavily influenced by broader market movements.
Relative Valuation: JANX is trading within its historical range and appears reasonably valued relative to its peers.
Key Levels & Action Items
Critical Price Levels:
- Support: $14.85 (lower Bollinger Band)
- Resistance: $16.79 (upper Bollinger Band)
Breakout/Breakdown Levels: A breakout above $16.79 could trigger further upside, while a breakdown below $15.30 could signal a trend reversal.
Time-Sensitive Catalysts: Earnings announcements and product launches could continue to drive the stock's price higher in the near term.
Risk Management: Stop-loss levels can be set around $14.85 or 5-7% below current price, considering position sizing and risk management strategies.
Please note that this report is for illustration purposes only and should not be taken as investment advice.
Generated
News
All JANX news →
Zacks Investment ResearchT3·1mo ago
BenzingaT3·9mo ago
The Motley FoolT3·23mo ago
BenzingaT3·29mo ago
BenzingaT3·29mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·30mo ago
BenzingaT3·30mo ago
Zacks Investment ResearchT3·30mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
14 of 14 under expected move
Avg Expected Move
16.15%
Avg Actual Move
3.16%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-09 | After-Close | 23.27% | 4.05% | 0.17x | Within |
| 2023-07-17 | After-Close | 15.10% | 3.05% | 0.20x | Within |
| 2023-11-07 | After-Close | 16.16% | 0.91% | 0.06x | Within |
| 2024-03-08 | After-Close | 13.74% | 0.40% | 0.03x | Within |
| 2024-05-08 | After-Close | 11.11% | 6.19% | 0.56x | Within |
| 2024-08-07 | After-Close | 15.87% | 3.40% | 0.21x | Within |
| 2024-11-06 | After-Close | 20.22% | 1.24% | 0.06x | Within |
| 2025-02-27 | After-Close | 17.96% | 2.75% | 0.15x | Within |
| 2025-05-08 | Pre-Market | 11.96% | 2.61% | 0.22x | Within |
| 2025-08-07 | Pre-Market | 20.16% | 6.62% | 0.33x | Within |
| 2025-11-06 | After-Close | 24.95% | 7.61% | 0.31x | Within |
| 2026-02-26 | After-Close | 17.93% | 1.38% | 0.08x | Within |
| 2026-05-07 | After-Close | 10.66% | 2.51% | 0.24x | Within |
| 2026-08-06 | After-Close | 6.99% | 1.55% | 0.22x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
JANX Options Activity & IV Rank
JANX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 94.8%
7-DTE IV: —
Expected Move: $3.55
7-DTE Move: $3.55
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 92
Put Volume: 254
P/C Volume: 2.761
BEARISH
Call OI: 964
Put OI: 537
P/C OI: 0.557
Total OI: 1,501
ATM Options Pricing
ATM Call: $1.68
ATM Put: $1.88
Call %: 10.0%
Put %: 11.2%
Chain Summary
Chain Volume: 10,138
Chain OI: 19,530
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 44th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
44%
vs own history
GEX tilt
-0.16
OI-weighted, today
Vanna tilt
-0.31
δ-sensitivity to IV
Charm tilt
+0.32
δ-decay vs time
Vanna tilt -0.31: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.32: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 19 ATM contracts, 4k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 97.1% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)100.0HighOct 26
Straddle Price (30 DTE)$3.55Oct 26
Beta Analysis
Risk Metrics
Beta: 1.1332
Alpha: -20.33%
Correlation: 0.1993
R-Squared: 4.0%
Stock Volatility: 72.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own JANX
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $30.6M | #461 of 1945 | +72.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $18.4M | #1192 of 6285 | +240.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $7.7M | #1774 of 3716 | +30.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $9K | #4040 of 4729 | -22.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
JANX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 62,398,424 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$4.44M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.74M | 39.28% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $1.17M | 26.24% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $589.82K | 13.28% | 2026-06-30 |
| 4 | Walleye Capital LLC | $459.26K | 10.34% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $264.19K | 5.95% | 2026-06-30 |
| 6 | Caption Management, LLC | $178.18K | 4.01% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $36.86K | 0.83% | 2026-06-30 |
| 8 | Citigroup Inc. Custodian | $3.07K | 0.07% | 2026-06-30 |
6 filers$3.44M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.40M | 69.80% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $394.75K | 11.46% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $337.92K | 9.81% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $156.67K | 4.55% | 2026-06-30 |
| 5 | Walleye Capital LLC | $147.46K | 4.28% | 2026-06-30 |
| 6 | Citigroup Inc. Custodian | $3.07K | 0.09% | 2026-06-30 |
JANX Insider Trading (Form 4)
Latest: 2026-07-31Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | David Alan Campbell | President and CEO | Gift (G) | −123,840 | — | EDGAR | |
| 2026-07-10 | David Alan Campbell | President and CEO | Exer (M) | +7,000 | $4.21 | $29.5K | EDGAR |
| 2026-06-12 | Eric Dobmeier | Director | Award (A) | +5,500 | — | EDGAR | |
| 2026-06-12 | Jake Simson | Director | Award (A) | +5,500 | — | EDGAR | |
| 2026-06-12 | Winston Kung | Director | Award (A) | +5,500 | — | EDGAR | |
| 2026-06-12 | Natasha Hernday | Director | Award (A) | +5,500 | — | EDGAR | |
| 2026-06-12 | Ronald W Barrett | Director | Award (A) | +5,500 | — | EDGAR | |
| 2026-06-12 | Vickie L Capps | Director | Award (A) | +5,500 | — | EDGAR | |
| 2026-06-12 | RA Capital Healthcare Fund LP | Director | Award (A) | +27,500 | — | EDGAR | |
| 2026-06-04 | Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | Sell (S) | −4,059 | $14.03 | -$56.9K | EDGAR |
| 2026-05-13 | Maria Dobek | Vice President, Accounting | Sell (S) | −2,038 | $14.17 | -$28.9K | EDGAR |
| 2026-02-04 | William Go | Chief Medical Officer | Award (A) | +44,000 | — | EDGAR | |
| 2026-01-02 | Charles M. Winter | Chief Technical Officer | Mixed | +26,199 | $13.73 | -$33.0K | EDGAR |
| 2026-01-02 | Zachariah McIver | Chief Medical Officer | Mixed | +26,286 | $13.73 | -$37.3K | EDGAR |
| 2026-01-02 | Maria Dobek | Vice President, Accounting | Mixed | +17,473 | $13.73 | -$20.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
JANX Insider Holdings
20 insiders · @ $16.69
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Rajeev M. Shah | Director | 10,031,081 | $167.42M | $326.71M | 2 | 2025-03-07 |
| 2 | RA Capital Nexus Fund II, L.P. | Director | 1,048,406 | $17.50M | $0 | 4 | 2025-06-13 |
| 3 | David Alan Campbell | President and CEO | 264,742 | $4.42M | -$6.61M | 13 | 2026-07-31 |
| 4 | Thomas DiRaimondo | Chief Scientific Officer | 155,825 | $2.60M | -$266.1K | 4 | 2026-01-02 |
| 5 | Sheila Gujrathi | Director | 118,889 | $1.98M | $0 | 6 | 2025-06-13 |
| 6 | Charles M. Winter | Chief Technical Officer | 106,321 | $1.77M | -$33.0K | 4 | 2026-01-02 |
| 7 | Andrew Hollman Meyer | Chief Business Officer | 83,095 | $1.39M | -$4.22M | 14 | 2026-01-02 |
| 8 | Vickie L Capps | Director | 79,598 | $1.33M | $0 | 7 | 2026-06-12 |
| 9 | Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | 75,941 | $1.27M | -$56.9K | 3 | 2026-06-04 |
| 10 | William Go | Chief Medical Officer | 44,000 | $734.4K | $0 | 1 | 2026-02-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
JANX Board & Officers
As of SEC filings through Jul 31, 2026Directors 14
- David Alan Campbell · since Jun 10, 2021
- Jake Simson · since Jun 10, 2021
- Peter Kolchinsky · since Jun 10, 2021
- RA Capital Healthcare Fund LP (entity) · since Jun 10, 2021
- Ra Capital Management, L.p. (entity) · since Jun 10, 2021
- Rajeev M. Shah · since Jun 10, 2021
- Sheila Gujrathi · since Jun 10, 2021
- Vickie L Capps · since Jun 10, 2021
- Alana B. McNulty · since Sep 7, 2021
- Ronald W Barrett · since Sep 7, 2021
- Winston Kung · since Sep 21, 2022
- RA Capital Nexus Fund II, L.P. (entity) · on file since Jun 2023
- Eric Dobmeier · since Jul 19, 2024
- Natasha Hernday · since Jul 19, 2024
Officers 8
- David Alan Campbell · President and CEO · listed since Jan 2024
- Maria Dobek · Vice President, Accounting · since Aug 8, 2024
- Andrew Hollman Meyer · Chief Business Officer · since Jun 10, 2021
- Charles M. Winter · Chief Technical Officer · since Jan 1, 2023
- Thomas DiRaimondo · Chief Scientific Officer · since Jan 1, 2024
- Zachariah McIver · Chief Medical Officer · since Jan 1, 2025
- Janeen Noel Doyle · Chief Corp. & Bus. Dev. Ofcr · since May 14, 2025
- William Go · Chief Medical Officer · since Jan 26, 2026
10% owners 4
- Peter Kolchinsky · since Jun 10, 2021
- RA Capital Healthcare Fund LP (entity) · since Jun 10, 2021
- Ra Capital Management, L.p. (entity) · since Jun 10, 2021
- Rajeev M. Shah · since Jun 10, 2021
Changes in the last 10 years (55)
| Jan 26, 2026 | William Go became Chief Medical Officer |
| May 14, 2025 | Janeen Noel Doyle became Chief Corp. & Bus. Dev. Ofcr |
| Jan 1, 2025 | Zachariah McIver became Chief Medical Officer |
| Oct 18, 2024 | Jay Lichter reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2024 | Avalon Ventures XI, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2024 | Avalon BioVentures SPV I, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2024 | Avalon BioVentures I, LP reported in an SEC filing no longer being a 10% owner |
| Aug 8, 2024 | Maria Dobek became Vice President, Accounting |
| Jul 19, 2024 | The company announced the departure of Jay Lichter from the board in an SEC filing |
| Jul 19, 2024 | Natasha Hernday became a director |
| Jul 19, 2024 | Eric Dobmeier became a director |
| Jan 3, 2024 | David Alan Campbell listed as President and CEO (previously Chief Executive Officer) in SEC filings |
| Jan 1, 2024 | Thomas DiRaimondo became Chief Scientific Officer |
| Nov 13, 2023 | Avalon BioVentures I, LP first on file as a 10% owner |
| Jun 21, 2023 | The company announced the departure of Wayne Godfrey as Chief Medical Officer in an SEC filing |
| Jun 16, 2023 | RA Capital Nexus Fund II, L.P. first on file as a director |
| Mar 27, 2023 | The company announced the departure of Peter A. Thompson from the board in an SEC filing |
| Jan 1, 2023 | Charles M. Winter became Chief Technical Officer |
| Sep 21, 2022 | Winston Kung became a director |
| Sep 21, 2022 | The company announced the departure of Stefan Heller from the board in an SEC filing |
| Mar 1, 2022 | Byron Robinson became Chief Strategy Officer |
| Dec 17, 2021 | OrbiMed Capital GP VII LLC first on file as a director |
| Sep 7, 2021 | Ronald W Barrett became a director |
| Sep 7, 2021 | Alana B. McNulty became a director |
| Jul 12, 2021 | Shahram Salek-Ardakani became Chief Scientific Officer |
| Jun 16, 2021 | Peter A. Thompson no longer listed as a 10% owner in SEC filings |
| Jun 16, 2021 | Bregua Corp reported in an SEC filing no longer being a 10% owner |
| Jun 14, 2021 | Peter A. Thompson first listed as a 10% owner in an SEC filing |
| Jun 10, 2021 | Wayne Godfrey became Chief Medical Officer |
| Jun 10, 2021 | Vickie L Capps became a director |
| Jun 10, 2021 | Tighe Reardon became a 10% owner |
| Jun 10, 2021 | Tighe Reardon became Acting Chief Financial Officer |
| Jun 10, 2021 | Stefan Heller became a director |
| Jun 10, 2021 | Sheila Gujrathi became a director |
| Jun 10, 2021 | Rajeev M. Shah became a director |
| Jun 10, 2021 | Rajeev M. Shah became a 10% owner |
| Jun 10, 2021 | Ra Capital Management, L.p. became a director |
| Jun 10, 2021 | Ra Capital Management, L.p. became a 10% owner |
| Jun 10, 2021 | RA Capital Healthcare Fund LP became a director |
| Jun 10, 2021 | RA Capital Healthcare Fund LP became a 10% owner |
| Jun 10, 2021 | Peter Kolchinsky became a director |
| Jun 10, 2021 | Peter Kolchinsky became a 10% owner |
| Jun 10, 2021 | Peter A. Thompson became a director |
| Jun 10, 2021 | Orbimed Advisors LLC became a director |
| Jun 10, 2021 | OrbiMed Genesis GP LLC became a director |
| Jun 10, 2021 | OrbiMed Capital GP VIII LLC became a director |
| Jun 10, 2021 | Jay Lichter became a director |
| Jun 10, 2021 | Jay Lichter became a 10% owner |
| Jun 10, 2021 | Jake Simson became a director |
| Jun 10, 2021 | David Alan Campbell became a director |
| Jun 10, 2021 | David Alan Campbell became Chief Executive Officer |
| Jun 10, 2021 | Bregua Corp became a 10% owner |
| Jun 10, 2021 | Avalon Ventures XI, L.P. became a 10% owner |
| Jun 10, 2021 | Avalon BioVentures SPV I, L.P. became a 10% owner |
| Jun 10, 2021 | Andrew Hollman Meyer became Chief Business Officer |
Not reported recently (7)
- Byron Robinson · Last reported as Chief Strategy Officer in an SEC filing dated Jan 3, 2025
- Tighe Reardon · Last reported as Acting Chief Financial Officer in an SEC filing dated Jun 5, 2024
- Shahram Salek-Ardakani · Last reported as Chief Scientific Officer in an SEC filing dated Jan 5, 2022
- OrbiMed Genesis GP LLC · Last reported as a director in an SEC filing dated Dec 30, 2021
- Orbimed Advisors LLC · Last reported as a director in an SEC filing dated Dec 30, 2021
- OrbiMed Capital GP VIII LLC · Last reported as a director in an SEC filing dated Dec 30, 2021
- OrbiMed Capital GP VII LLC · Last reported as a director in an SEC filing dated Dec 17, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
JANX Proposed Insider Sales (Form 144)
Latest: 2026-06-02
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | Janeen Noel Doyle | Officer | 4,059 | $56.9K | 2026-06-02 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-04-13 | ANDY MEYER | Former Affiliate | 1,877 | $28.2K | 2026-04-13 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-04-02 | ZACHARIAH A MCIVER | Former Officer | 74,802 | $1.10M | 2026-04-02 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-01-26 | ANDY MEYER | Former Affiliate | 178,767 | $2.60M | 2026-01-26 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-01-23 | ANDY MEYER | Former Affiliate | 118,122 | $1.74M | 2026-01-23 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-12-15 | BYRON C ROBINSON | Officer | 16,666 | $258.4K | 2025-12-15 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-12-08 | BYRON C ROBINSON | Officer | 50,000 | $826.0K | 2025-12-08 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-12-02 | BYRON C ROBINSON | Officer | 63,125 | $1.03M | 2025-12-02 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-12-01 | ANDREW MEYER | Officer | 3,333 | $113.6K | 2025-12-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-11-14 | ANDREW MEYER | Officer | 3,333 | $91.5K | 2025-11-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
54 ETFs hold JANX
25 shown · $120.65M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $26.8M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.19% | $20.1M | $10.4B | 2026-10-23 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $19.8M | $74.6B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $9.6M | — | 2026-09-30 |
| 5 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.07% | $7.3M | $10.7B | 2026-10-23 |
| 6 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.05% | $7.3M | $13.9B | 2026-10-23 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $4.8M | — | 2026-09-30 |
| 8 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $3.9M | — | 2026-10-23 |
| 9 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $3.3M | — | 2026-05-31 |
| 10 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 0.86% | $2.8M | $321.2M | 2026-10-23 |
| 11 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.03% | $2.3M | — | 2026-10-23 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.3M | — | 2026-09-30 |
| 13 | FBCG Fidelity Blue Chip Growth ETF | Nport | 0.03% | $1.9M | — | 2026-07-31 |
| 14 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.1M | $96.5B | 2026-10-23 |
| 15 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.04% | $1.1M | $3.2B | 2026-10-23 |
| 16 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.33% | $909,657 | — | 2026-05-31 |
| 17 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.02% | $898,274 | $4.2B | 2026-10-23 |
| 18 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.14% | $781,770 | — | 2026-10-26 |
| 19 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.06% | $761,581 | — | 2026-09-30 |
| 20 | CANC Tema Oncology ETF | Nport | 0.43% | $751,706 | — | 2026-05-31 |
| 21 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $484,029 | — | 2026-07-31 |
| 22 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $405,850 | — | 2026-05-31 |
| 23 | RSSL Global X Russell 2000 ETF | Global X | 0.03% | $384,521 | — | 2026-10-26 |
| 24 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.01% | $359,789 | $3.8B | 2026-10-23 |
| 25 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.75% | $347,742 | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.64
TTM Revenue
$24.00M
TTM Net Income
$-102.59M
TTM Op. Cash Flow
$-41.25M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $10.27M | $-21.97M | $-0.35 | $12.48M |
| Q1 '26 | 2026-03-31 | $3.73M | $-24.36M | $-0.39 | $-12.34M |
| Q4 '25 | 2025-12-31 | $0.00 | $-31.95M | $-0.51 | $-28.54M |
| Q3 '25 | 2025-09-30 | $10.00M | $-24.31M | $-0.39 | $-12.86M |
| Q2 '25 | 2025-06-30 | — | $-33.86M | $-0.55 | $-23.81M |
| Q1 '25 | 2025-03-31 | — | $-23.51M | $-0.38 | $-17.02M |
| Q4 '24 | 2024-12-31 | $0.00 | $-20.22M | $-0.35 | $-16.73M |
| Q3 '24 | 2024-09-30 | $439.00K | $-28.06M | $-0.51 | $-2.23M |
| Q2 '24 | 2024-06-30 | $8.90M | $-5.96M | $-0.11 | $-10.02M |
| Q1 '24 | 2024-03-31 | $1.25M | $-14.76M | $-0.30 | $-14.84M |
| Q4 '23 | 2023-12-31 | $2.46M | $-11.76M | $-0.24 | $-9.90M |
| Q3 '23 | 2023-09-30 | $2.52M | $-11.57M | $-0.25 | $-11.71M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.12
P/S
43.39
EV/EBITDA
—
EV/Sales
42.24
ROE
-11.1%
ROA
-10.2%
Div Yield
0.00%
FCF Yield
-3.96%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.04B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
5.68M
SI % of Float
13.36%
Days to Cover
5.86
Short Vol Ratio
57.1%
Free Float
42.55M
Float %
69.6%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14